CURRENT ROLE OF PHARMACOLOGIC THERAPY FOR PATIENTS WITH PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA
Identifieur interne : 003C08 ( Main/Exploration ); précédent : 003C07; suivant : 003C09CURRENT ROLE OF PHARMACOLOGIC THERAPY FOR PATIENTS WITH PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA
Auteurs : Magdy Basta [Canada] ; Magdy Mbbch [Canada] ; George J. Klein [Canada] ; Raymond Yee [Canada] ; Andrew Krahn [Canada] ; John Lee [Canada]Source :
- Cardiology Clinics [ 0733-8651 ] ; 1997.
Abstract
The advent of radiofrequency catheter ablation has dramatically changed the approach to all arrhythmias, especially the supraventricular arrhythmias. 21,51 The efficacy and safety of the procedure, along with the appeal of achieving cure, have led to an ever-increasing role of catheter ablation for management of supraventricular tachycardia (SVT). The effectiveness of ablation as a therapeutic modality has resulted in a marked decline of the traditional role of drug therapy. In addition, the increasing use of curative therapy is likely to result in a further decline in the prevalence of many of the SVTs in clinical practice.The progress in the pharmacotherapy of SVT has been less dramatic. One of the major breakthroughs has been the establishment of the role of adenosine in the acute management of SVT. 6,15 Moreover, the issue of antiarrhythmic drug safety has been a major concern given the potential for proarrhythmia with virtually every antiarrhythmic drug. This article reviews the current role of pharmacotherapy in the management of SVT in this era of successful catheter ablation.
Url:
DOI: 10.1016/S0733-8651(05)70363-5
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000666
- to stream Istex, to step Curation: 000666
- to stream Istex, to step Checkpoint: 001702
- to stream Main, to step Merge: 004260
- to stream Main, to step Curation: 003C08
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">CURRENT ROLE OF PHARMACOLOGIC THERAPY FOR PATIENTS WITH PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA</title><author><name sortKey="Basta, Magdy" sort="Basta, Magdy" uniqKey="Basta M" first="Magdy" last="Basta">Magdy Basta</name></author><author><name sortKey="Mbbch, Magdy" sort="Mbbch, Magdy" uniqKey="Mbbch M" first="Magdy" last="Mbbch">Magdy Mbbch</name></author><author><name sortKey="Klein, George J" sort="Klein, George J" uniqKey="Klein G" first="George J." last="Klein">George J. Klein</name></author><author><name sortKey="Yee, Raymond" sort="Yee, Raymond" uniqKey="Yee R" first="Raymond" last="Yee">Raymond Yee</name></author><author><name sortKey="Krahn, Andrew" sort="Krahn, Andrew" uniqKey="Krahn A" first="Andrew" last="Krahn">Andrew Krahn</name></author><author><name sortKey="Lee, John" sort="Lee, John" uniqKey="Lee J" first="John" last="Lee">John Lee</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:CF256B2DDDFD74CC183B76E767D0CB56921C3A63</idno><date when="1997" year="1997">1997</date><idno type="doi">10.1016/S0733-8651(05)70363-5</idno><idno type="url">https://api-v5.istex.fr/document/CF256B2DDDFD74CC183B76E767D0CB56921C3A63/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000666</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000666</idno><idno type="wicri:Area/Istex/Curation">000666</idno><idno type="wicri:Area/Istex/Checkpoint">001702</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001702</idno><idno type="wicri:doubleKey">0733-8651:1997:Basta M:current:role:of</idno><idno type="wicri:Area/Main/Merge">004260</idno><idno type="wicri:Area/Main/Curation">003C08</idno><idno type="wicri:Area/Main/Exploration">003C08</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">CURRENT ROLE OF PHARMACOLOGIC THERAPY FOR PATIENTS WITH PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA</title><author><name sortKey="Basta, Magdy" sort="Basta, Magdy" uniqKey="Basta M" first="Magdy" last="Basta">Magdy Basta</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Cardiology, University of Western Ontario, London, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Mbbch, Magdy" sort="Mbbch, Magdy" uniqKey="Mbbch M" first="Magdy" last="Mbbch">Magdy Mbbch</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Cardiology, University of Western Ontario, London, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Klein, George J" sort="Klein, George J" uniqKey="Klein G" first="George J." last="Klein">George J. Klein</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Cardiology, University of Western Ontario, London, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Yee, Raymond" sort="Yee, Raymond" uniqKey="Yee R" first="Raymond" last="Yee">Raymond Yee</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Cardiology, University of Western Ontario, London, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Krahn, Andrew" sort="Krahn, Andrew" uniqKey="Krahn A" first="Andrew" last="Krahn">Andrew Krahn</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Cardiology, University of Western Ontario, London, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Lee, John" sort="Lee, John" uniqKey="Lee J" first="John" last="Lee">John Lee</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Cardiology, University of Western Ontario, London, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Cardiology Clinics</title><title level="j" type="abbrev">CCL</title><idno type="ISSN">0733-8651</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1997">1997</date><biblScope unit="volume">15</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="587">587</biblScope><biblScope unit="page" to="597">597</biblScope></imprint><idno type="ISSN">0733-8651</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0733-8651</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">The advent of radiofrequency catheter ablation has dramatically changed the approach to all arrhythmias, especially the supraventricular arrhythmias. 21,51 The efficacy and safety of the procedure, along with the appeal of achieving cure, have led to an ever-increasing role of catheter ablation for management of supraventricular tachycardia (SVT). The effectiveness of ablation as a therapeutic modality has resulted in a marked decline of the traditional role of drug therapy. In addition, the increasing use of curative therapy is likely to result in a further decline in the prevalence of many of the SVTs in clinical practice.The progress in the pharmacotherapy of SVT has been less dramatic. One of the major breakthroughs has been the establishment of the role of adenosine in the acute management of SVT. 6,15 Moreover, the issue of antiarrhythmic drug safety has been a major concern given the potential for proarrhythmia with virtually every antiarrhythmic drug. This article reviews the current role of pharmacotherapy in the management of SVT in this era of successful catheter ablation.</div></front></TEI><affiliations><list><country><li>Canada</li></country></list><tree><country name="Canada"><noRegion><name sortKey="Basta, Magdy" sort="Basta, Magdy" uniqKey="Basta M" first="Magdy" last="Basta">Magdy Basta</name></noRegion><name sortKey="Klein, George J" sort="Klein, George J" uniqKey="Klein G" first="George J." last="Klein">George J. Klein</name><name sortKey="Krahn, Andrew" sort="Krahn, Andrew" uniqKey="Krahn A" first="Andrew" last="Krahn">Andrew Krahn</name><name sortKey="Lee, John" sort="Lee, John" uniqKey="Lee J" first="John" last="Lee">John Lee</name><name sortKey="Mbbch, Magdy" sort="Mbbch, Magdy" uniqKey="Mbbch M" first="Magdy" last="Mbbch">Magdy Mbbch</name><name sortKey="Yee, Raymond" sort="Yee, Raymond" uniqKey="Yee R" first="Raymond" last="Yee">Raymond Yee</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003C08 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003C08 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:CF256B2DDDFD74CC183B76E767D0CB56921C3A63
|texte= CURRENT ROLE OF PHARMACOLOGIC THERAPY FOR PATIENTS WITH PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA
}}
| This area was generated with Dilib version V0.6.29. |  |